Citations

Mayo Clinic

Clear

4058 citation(s) found for "Pršić, Elizabeth".

Lymphokine‐activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
Jennings, V.A., Ilett, Elizabeth J. , Scott, Karen J. , Vile, Richard G. , Pandha, Hardev , Harrington, Kevin J. , Young, Alexandria N., Hall, G.D., Selby, Peter J. , Errington‐Mais, Fiona , Melcher, Alan , West, Emma J. , Coffey, Matt C. , Jennings, Victoria A. , Ilett, Elizabeth J , Errington-Mais, Fiona , Melcher, Alan A , Harrington, Kevin

International Journal of Cancer | August 26, 2013 | Volume: 134 | Issue: 5 | Pages: 1091-1101

10.1002/ijc.28450 | PMID 23982804 Get It

Reovirus is an oncolytic virus (OV), which acts by both direct tumor cell killing and priming of antitumor immunity. A major obstacle for effective oncolytic virotherapy is effective delivery of OV to tumor cells. Ovarian cancer is often confined to the peritoneal cavity and therefore i.p. delivery of reovirus may provide the ideal locoregional delivery, avoiding systemic dissemination. However, ovarian cancer is associated with an accumulation of ascitic fluid, which may interfere with oncolytic viral therapy. Here, we investigated the effect of ascites on reovirus‐induced oncolysis against primary ovarian cancer cells and ovarian cancer cell lines. In the absence of ascites, reovirus was cytotoxic against ovarian cancer cells; however, cytotoxicity was abrogated in the presence of ascitic fluid. Neutralizing antibodies (NAb) were identified as the cause of this inhibition. Loading OV onto cell carriers may facilitate virus delivery in the presence of NAb and immune cells which have their own antitumor effector activity are particularly appealing. Immature dendritic cells (iDC), Lymphokine‐activated killer (LAK) cells and LAKDC cocultures were tested as potential carriers for reovirus for tumor cell killing and immune cell priming. Reovirus‐loaded LAKDC, and to a lesser degree iDC, were able to: (i) protect from NAb and hand‐off reovirus for tumor cell killing; (ii) induce a proinflammatory cytokine milieu (IFNɣ, IL‐12, IFNα and TNFα) and (iii) generate an innate and specific antitumor adaptive immune response. Hence, LAKDC pulsed with reovirus represent a novel, clinically practical treatment for ovarian cancer to maximise both direct and innate/adaptive immune‐mediated tumor cell killing.
Utility of minimum F‐wave latencies compared with F‐estimates and absolute reference values in S1 radiculopathies: Are they still needed?
Mauricio, Elizabeth A. , Dimberg, Elliot L., Rubin, Devon I., Mauricio, Elizabeth A.

Muscle & Nerve | August 20, 2013 | Volume: 49 | Issue: 6 | Pages: 809-813

10.1002/mus.23992 | PMID 23963973 Get It

ABSTRACTIntroduction: The utility of F‐waves in assessing radiculopathies is debated. The aim of this study is to determine the frequency of abnormal minimum tibial F‐wave latencies compared to an F‐estimate and an absolute reference value in patients with electromyography (EMG) confirmed S1 radiculopathies. Methods: A retrospective review of F‐waves in patients with an EMG‐confirmed isolated S1 radiculopathy was performed. The minimum and mean latencies of 8 tibial F‐waves were compared with the calculated F‐estimate and to an absolute reference value, and the frequencies of abnormal responses were determined. Results: Of the 50 patients with an S1 radiculopathy, 4% had prolongation of the minimum reproducible F‐wave latency, and 8% had prolongation of the mean latency relative to the calculated F‐estimate. Conclusions: The minimum and mean F‐wave latencies are infrequently abnormal when compared with an estimated F‐wave latency in S1 radiculopathies and are insensitive in the assessment of S1 nerve root injury. Muscle Nerve 49: 809–813, 2014
A new statistic for identifying batch effects in high-throughput genomic data that uses guided principal component analysis
Reese, Sarah E. , Archer, Kellie J. , Therneau, Terry M. , Atkinson, Elizabeth J. , Vachon, Celine M. , Kocher, Jean‐Pierre , Eckel‐Passow, Jeanette E. , Vachon, Celine M. , Andrade, Mariza de

Bioinformatics | August 19, 2013 | Volume: 29 | Issue: 22 | Pages: 2877-2883

10.1093/bioinformatics/btt480 | PMID 23958724 Get It

Abstract Motivation: Batch effects are due to probe-specific systematic variation between groups of samples (batches) resulting from experimental features that are not of biological interest. Principal component analysis (PCA) is commonly used as a visual tool to determine whether batch effects exist after applying a global normalization method. However, PCA yields linear combinations of the variables that contribute maximum variance and thus will not necessarily detect batch effects if they are not the largest source of variability in the data. Results: We present an extension of PCA to quantify the existence of batch effects, called guided PCA (gPCA). We describe a test statistic that uses gPCA to test whether a batch effect exists. We apply our proposed test statistic derived using gPCA to simulated data and to two copy number variation case studies: the first study consisted of 614 samples from a breast cancer family study using Illumina Human 660 bead-chip arrays, whereas the second case study consisted of 703 samples from a family blood pressure study that used Affymetrix SNP Array 6.0. We demonstrate that our statistic has good statistical properties and is able to identify significant batch effects in two copy number variation case studies. Conclusion: We developed a new statistic that uses gPCA to identify whether batch effects exist in high-throughput genomic data. Although our examples pertain to copy number data, gPCA is general and can be used on other data types as well. Availability and implementation: The gPCA R package (Available via CRAN) provides functionality and data to perform the methods in this article. Contact: reesese@vcu.edu or eckel@mayo.edu Supplementary information: Supplementary data are available at Bioinformatics online.
Trends in Fracture Incidence: A Population-Based Study Over 20 Years
Amin, Shreyasee , Achenbach, Sara J., Atkinson, Elizabeth J. , Khosla, Sundeep , Melton, L. Joseph , Khosla, Sundeep

Journal of Bone and Mineral Research | August 19, 2013 | Volume: 29 | Issue: 3 | Pages: 581-589

10.1002/jbmr.2072 | PMID 23959594 Get It

ABSTRACT To assess recent trends in fracture incidence from all causes at all skeletal sites, we used the comprehensive (inpatient and outpatient) data resources of the Rochester Epidemiology Project to estimate rates for Olmsted County, MN, USA, residents in 2009 to 2011 compared with similar data from 1989 to 1991. During the 3-year study period, 2009 to 2011, 3549 residents ≥50 years of age experienced 5244 separate fractures. The age- and sex-adjusted (to the 2010 US white population) incidence of any fracture was 2704 per 100,000 person-years (95% confidence interval [CI] 2614 to 2793) and that for all fractures was 4017 per 100,000 (95% CI 3908 to 4127). Fracture incidence increased with age in both sexes, but age-adjusted rates were 49% greater among the women. Overall, comparably adjusted fracture incidence rates increased by 11% (from 3627 to 4017 per 100,000 person-years; p = 0.008) between 1989 to 1991 and 2009 to 2011. This was mainly attributable to a substantial increase in vertebral fractures (+47% for both sexes combined), which was partially offset by a decline in hip fractures (−25%) among the women. There was also a 26% reduction in distal forearm fractures among the women; an increase in distal forearm fractures among men aged 50 years and over was not statistically significant. The dramatic increase in vertebral fractures, seen in both sexes and especially after age 75 years, was attributable in part to incidentally diagnosed vertebral fractures. However, the fall in hip fracture incidence, observed in most age groups, continues the steady decline observed among women in this community since 1950. More generally, these data indicate that the dramatic increases in the incidence of fractures at many skeletal sites that were observed decades ago have now stabilized. © 2014 American Society for Bone and Mineral Research.
Effects of Cardiac Resynchronization Therapy on Muscle Sympathetic Nerve Activity
Kuniyoshi, Ricardo , Filho, Martino Martinelli , Negrão, Carlos Eduardo , Siqueira, Sérgio , Rondon, Maria Urbana Pinto Brandão , Trombetta, Ivani C. , Kuniyoshi, Fatima H. Sert , NISHIOKA, SILVANA A. D’ÓRIO, Costa, Roberto , Tamaki, Wagner Tetsuji, Crevelari, Elizabeth, Peixoto, Giselle de Lima , Ramires, José Antônio Franchini , Laterza, Mateus Camaroti , Nishioka, Silvana, Filho, Roberto Kalil , Sert Kuniyoshi, Fatima H

Pacing and Clinical Electrophysiology | August 16, 2013 | Volume: 37 | Issue: 1 | Pages: 11-18

10.1111/pace.12254 | PMID 23952584 Get It

IntroductionMuscle sympathetic nerve activity (MSNA) is an independent prognostic marker in patients with heart failure (HF). Therefore, its relevance to the treatment of HF patients is unquestionable.ObjectivesIn this study, we investigated the effects of cardiac resynchronization therapy (CRT) on MSNA response at rest and during exercise in patients with advanced HF.MethodsWe assessed 11 HF patients (51 ± 3.4 years; New York Heart Association class III–IV; left ventricular ejection fraction 27.8 ± 2.2%; optimal medical therapy) submitted to CRT. Evaluations were made prior to and 3 months after CRT. MSNA was performed at rest and during moderate static exercise (handgrip). Peak oxygen consumption (VO2) was evaluated by means of cardiopulmonary exercise test. HF patients with advanced NYHA class without CRT and healthy individuals were also studied.ResultsCRT reduced MSNA at rest (48.9 ± 11.1 bursts/min vs 33.7 ± 15.3 bursts/min, P < 0.05) and during handgrip exercise (MSNA 62.3 ± 13.1 bursts/min vs 46.9 ± 14.3 bursts/min, P < 0.05). Among HF patients submitted to CRT, the peak VO2 increased (12.9 ± 2.8 mL/kg/min vs 16.5 ± 3.9 mL/kg/min, P < 0.05) and an inverse correlation between peak VO2 and resting MSNA (r = –0.74, P = 0.01) was observed.ConclusionsIn patients with advanced HF and severe systolic dysfunction: (1) a significant reduction of MSNA (at rest and during handgrip) occurred after CRT, and this behavior was significantly superior to HF patients receiving only medical therapy; (2) MSNA reduction after CRT had an inverse correlation with O2 consumption outcomes.
Activation of a muscle-specific actin gene promoter in serum-stimulated fibroblasts.
Stoflet, Elizabeth S., Schmidt, Lucy J., Elder, Paula K., Korf, Gina M., Foster, Douglas N., Strauch, Arthur R., Getz, Michael J.

Molecular Biology of the Cell | August 16, 2013 | Volume: 3 | Issue: 10 | Pages: 1073-1083

10.1091/mbc.3.10.1073 | PMID 1421567 Get It

Treatment of AKR-2B mouse fibroblasts with serum growth factors or inhibitors of protein synthesis, such as cycloheximide, results in a stimulation of cytoskeletal beta-actin transcription but has no effect on transcription of muscle-specific isotypes, such as the vascular smooth muscle (VSM) alpha-actin gene. Deletion mapping and site-specific mutagenesis studies demonstrated that a single "CArG" element of the general form CC(A/T)6GG was necessary and possibly sufficient to impart serum and cycloheximide-inducibility to the beta-actin promoter. Although the VSM alpha-actin promoter exhibits at least three similar sequence elements, it remained refractory to serum and cycloheximide induction. However, deletion of a 33 base pair sequence between -191 and -224 relative to the transcription start site resulted in the transcriptional activation of this muscle-specific promoter in rapidly growing or serum-stimulated fibroblasts. Although the activity of this truncated promoter was potentiated by cycloheximide in a manner indistinguishable from that of the beta-actin promoter, this was dependent on a more complex array of interacting elements. These included at least one CArG box and a putative upstream activating element closely associated with the -191 to -224 inhibitory sequences. These results demonstrate that the expression of a muscle-specific actin gene in fibroblasts is suppressed by a cis-acting negative control element and that in the absence of this element, the promoter is responsive to growth factor-induced signal transduction pathways.
Disseminated microsporidiosis in a renal transplant recipient: case report and review of the literature
Nagpal, Avish , Pritt, Bobbi S. , Lorenz, Elizabeth C. , Amer, Hatem , Nasr, Samih H. , Cornell, Lynn D. , Iqbal, Seher, Wilhelm, Mark , Amer, Hatem , Pritt, Bobbi S , Cornell, Lynn

Transplant Infectious Disease | August 16, 2013 | Volume: 15 | Issue: 5 | Pages: 526-532

10.1111/tid.12119 | PMID 23947513 Get It

AbstractMicrosporidia are opportunistic pathogens that usually cause a limited disease in the gastrointestinal tract. Occasionally, they can cause disseminated disease. In solid organ transplant recipients, disseminated disease has been reported only rarely. We describe a 68‐year‐old woman who presented with fever, cough, and acute kidney injury 6 months after kidney transplantation. Dissemination was confirmed by identification of microsporidial spores in urine and bronchoalveolar lavage fluid. Polymerase chain reaction analysis identified the species as Encephalitozoon cuniculi.
Search for genetic modifiers of IRF6 and genotype–phenotype correlations in Van der Woude and popliteal pterygium syndromes
Leslie, Elizabeth J. , Mancuso, Jennifer L., Schutte, Brian C. , Cooper, Margaret E., Durda, Kate, L’Heureux, Jamie, Zucchero, Theresa M., Marazita, Mary L. , Murray, Jeffrey C.

American Journal of Medical Genetics Part A | August 15, 2013 | Volume: 161 | Issue: 10 | Pages: 2535-2544

10.1002/ajmg.a.36133 | PMID 23949966 Get It

ABSTRACTVan der Woude syndrome is the most common form of syndromic orofacial clefting, accounting for 1–2% of all patients with cleft lip and/or cleft palate. Van der Woude and popliteal pterygium syndromes are caused by mutations in IRF6, but phenotypic variability within and among families with either syndrome suggests that other genetic factors contribute to the phenotypes. The aim of this study was to identify common variants acting as genetic modifiers of IRF6 as well as genotype–phenotype correlations based on mutation type and location. We identified an association between mutations in the DNA‐binding domain of IRF6 and limb defects (including pterygia). Although we did not detect formally significant associations with the genes tested, borderline associations suggest several genes that could modify the VWS phenotype, including FOXE1, TGFB3, and TFAP2A. Some of these genes are hypothesized to be part of the IRF6 gene regulatory network and may suggest additional genes for future study when larger sample sizes are also available. We also show that families with the Van de Woude phenotype but in whom no mutations have been identified have a lower frequency of cleft lip, suggesting there may be locus and/or mutation class differences in Van de Woude syndrome. © 2013 Wiley Periodicals, Inc.
Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases
Andrianifahanana, Mahefatiana, Wilkes, Mark C. , Rahimi, Rod A. , Repellin, Claire E. , Edens, Maryanne, Wittenberger, Joshua, Yin, Xueqian , Maidl, Elizabeth, Becker, Jackson, Leof, Edward B. , Gupta, Shiv K.

The FASEB Journal | August 3, 2013 | Volume: 27 | Issue: 11 | Pages: 4444-4454

10.1096/fj.12-224907 | PMID 23913859 Get It

Transforming growth factor β (TGFβ) has significant profibrotic activity both in vitro and in vivo . This reflects its capacity to stimulate fibrogenic mediators and induce the expression of other profibrotic cytokines such as platelet‐derived growth factor (PDGF) and epidermal growth factor (EGF/ErbB) ligands. Here we address both the mechanisms by which TGFβ induced ErbB ligands and the physiological significance of inhibiting multiple TGFβ‐regulated processes. The data document that ErbB ligand induction requires PDGF receptor (PDGFR) mediation and engages a positive autocrine/paracrine feedback loop via ErbB receptors. Whereas PDGFRs are essential for TGFβ‐stimulated ErbB ligand up‐regulation, TGFβ‐specific signals are also required for ErbB receptor activation. Subsequent profibrotic responses are shown to involve the cooperative action of PDGF and ErbB signaling. Moreover, using a murine treatment model of bleomycin‐induced pulmonary fibrosis we found that inhibition of TGFβ/PDGF and ErbB pathways with imatinib plus lapatinib, respectively, not only prevented myofibroblast gene expression to a greater extent than either drug alone, but also essentially stabilized gas exchange (oxygen saturation) as an overall measure of lung function. These observations provide important mechanistic insights into profibrotic TGFβ signaling and indicate that targeting multiple cytokines represents a possible strategy to ameliorate organ fibrosis dependent on TGFβ.—Andrianifahanana, M., Wilkes, M. C., Gupta, S. K., Rahimi, R. R., Repellin, C. E., Edens, M., Wittenberger, J., Yin, X., Maidl, E., Becker, J., Leof, E. B. Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. FASEB J . 27, 4444‐4454 (2013). www.fasebj.org
Assessing calibration of prognostic risk scores
Crowson, Cynthia S. , Atkinson, Elizabeth J. , Therneau, Terry M.

Statistical Methods in Medical Research | August 1, 2013 | Volume: 25 | Issue: 4 | Pages: 1692-1706

10.1177/0962280213497434 | PMID 23907781 Get It

Current methods used to assess calibration are limited, particularly in the assessment of prognostic models. Methods for testing and visualizing calibration (e.g. the Hosmer–Lemeshow test and calibration slope) have been well thought out in the binary regression setting. However, extension of these methods to Cox models is less well known and could be improved. We describe a model-based framework for the assessment of calibration in the binary setting that provides natural extensions to the survival data setting. We show that Poisson regression models can be used to easily assess calibration in prognostic models. In addition, we show that a calibration test suggested for use in survival data has poor performance. Finally, we apply these methods to the problem of external validation of a risk score developed for the general population when assessed in a special patient population (i.e. patients with particular comorbidities, such as rheumatoid arthritis).